Overview

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2027-12-15
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Incyte Corporation
Treatments:
Axitinib